Br J Sports Med 2022 Jun 29. Epub 2022 Jun 29.
General Practice/Centre for Public Health, Queen's University Belfast, Belfast, UK
Rheumatol Ther 2022 Jul 26. Epub 2022 Jul 26.
Institute of Neurological Sciences IFNAP, Nordostpark 51, 90411, Nuremberg, Germany.
Osteoarthritis is the most common joint disorder affecting over 300 million people worldwide. It typically affects the knees and the hips, and is characterized by a loss in normal joint movement, stiffness, swelling, and pain in patients. The current gold standard therapy for osteoarthritis targets pain management using nonsteroidal anti-inflammatory drugs (NSAIDs). Read More
Implement Sci 2022 05 16;17(1):32. Epub 2022 May 16.
KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.
Background: Medication errors are likely common in low- and middle-income countries (LMICs). In neonatal hospital care where the population with severe illness has a high mortality rate, around 14.9% of drug prescriptions have errors in LMICs settings. Read More
Am J Clin Dermatol 2022 May 14;23(3):365-383. Epub 2022 May 14.
Regeneron Pharmaceuticals, Inc., 77 Old Saw Mill River Road, Tarrytown, NY, 10591, USA.
Background: For adolescent patients (aged ≥ 12 to < 18 years) with uncontrolled moderate-to-severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with placebo, with an acceptable safety profile. However, long-term data on the approved dose regimens of dupilumab in adolescents with AD are lacking.Objectives: This open-label extension study (LIBERTY AD PED-OLE, NCT02612454) reports the long-term safety, efficacy, and pharmacokinetics of dupilumab in adolescents with moderate-to-severe AD who had participated in dupilumab parent trials. Read More
Adv Ther 2022 04 24;39(4):1810-1831. Epub 2022 Feb 24.
The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA.
Introduction: Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis (MS) with the same active metabolite as dimethyl fumarate (DMF). DRF has a safety/efficacy profile similar to DMF but with improved gastrointestinal (GI) tolerability and low (< 1%) treatment discontinuation due to GI adverse events (AEs). Efficacy and safety outcomes in patients who switched to DRF from other disease-modifying therapies (DMTs) have not been evaluated. Read More